ArticleTranslational vision science & technology2025
The Safety and Tolerability of a Single Scleral Treatment With a Cooling Device in Rabbits.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of an Ophthalmic Cooling Device on Corneal Immune and Sensory Nerve Features in Chronic Ocular Surface Pain: A Prospective, Feasibility Study.Ophthalmology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the preclinical safety of a single treatment of a topical scleral cooling device. Methods: Two Good Laboratory Practice prospective preclinical device safety studies were performed: study 1 in normal healthy rabbit eyes (n = 5) and study 2 in healthy rabbit eyes that underwent a surgically induced corneal epithelial defect (n = 3). Following sedation, eyes were treated for 10 minutes by applying the cooling device to the sclera. Key assessments for both studies included clinical observations, Schirmer's I and II tests, ophthalmic examinations, intraocular pressure (IOP) measurements, and histopathology. Study 1 assessments were performed on days -3, 7, 14, 21, 28, 42 (±2 days), and 56 (±2 days). In study 2, a 3-mm diameter corneal defect was created in both eyes of each animal 14 days after the cooling device application. Corneal fluorescein staining was monitored at 3, 6, 24, 30, 48, 54, and 72 hours after defect creation. Results: Minimal changes in conjunctival redness, peripheral corneal haze, and fluorescein staining were observed, which completely self-resolved within 4 weeks after treatment. Schirmer's I and II and IOP results were within normal ranges in all animals. All epithelial defects in both groups had fully healed within 48 hours. Conclusions: No adverse effects were observed within 8 weeks following a single scleral application of the topical cooling device in rabbit eyes. Translational Relevance: This article introduces a novel ocular cooling device for the treatment of chronic ocular surface pain, a condition with a considerable unmet need for more effective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.